Leiomyosarcomas are a group of highly heterogeneous tumors differing in locations, pathological features, response to therapy, and propensity for metastasis. Historically, leiomyosarcomas originating from the gastrointestinal (GI) tract do not respond to conventional chemotherapy, whereas, leiomyosarcomas arising from other organ systems are more likely to respond to doxorubicin-based therapies. This observation was refined by others and it became clear that patients with (gastrointestinal stromal tumor) GIST had not only poor response rates to standard investigational therapy, but also a worse overall outcome. Recent discoveries made by basic scientists, pathologists and clinical investigators has led to an understanding of the biological importance of c-kit in GISTs and the development of one of the most exciting examples of targeted therapy to date. The success of the c-kit tyrosine kinase inhibitor STI-571 (Gleevec) has caught the attention of the scientific community. Understanding the mechanisms of response and resistance to STI-571 will broaden our understanding of cancer biology and lead to strategic approaches in the treatment of other malignancies.
The aims of this study are to identify molecular events at the level of gene expression that are associated with prognosis, metastasis, and the dramatic responses to STI-571 that have been observed with GIST but not leiomyosarcomas arising outside of the GI tract. We will couple gene-expression-profiling studies with high throughput confirmation and functional validation studies to gain understanding of the mechanisms underlying the important clinical phenotypes. We will test three related hypotheses. 1) There are key cellular pathway genes whose differential expressions are responsible for the different prognoses of leiomyosarcoma and GISTs; 2) There are key metastasis-regulating genes whose expressions are responsible for different metastasis potentials of leiomyosarcoma; 3) There are key genes that regulate response to STI-571 treatment in GIST but resistance to STI-571 in leiomyosarcomas arising outside the GI tract. In this proposal, we will test these 3 hypotheses with 3 specific aims taking advantage of high throughput transcriptome profiling technologies, high throughput tissue microarray and real-time polymerase chain reaction (PCR) validation, and in vitro gene perturbation functional studies.
Aim 1 : To generate transcriptome data using a microarray technique and to identify genes associated with extremity leiomyosarcomas (including retroperitoneal, vascular, uterine and extremity sites of origin) and GISTs.
Aim 2 : To identify genes that are involved in leiomyosarcoma and GIST metastasis and functionally test those genes in an in vitro invasion assay.
Aim 3 : To identify genes that regulate cellular response and resistance to the tyrosine kinase inhibitor STI-571, a drug for treating GISTs that have c-kit mutations and activation. Through this hypothesis-driven and discovery-driven program, we anticipate discovery of markers for clinical prediction as well as understanding of the molecular basis for those important clinical phenotypes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098570-03
Application #
6912820
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Thurin, Magdalena
Project Start
2003-07-01
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
3
Fiscal Year
2005
Total Cost
$324,628
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Neurology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ylipää, Antti; Hunt, Kelly K; Yang, Jilong et al. (2011) Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer 117:380-9
Yang, Jilong; Eddy, James A; Pan, Yuan et al. (2010) Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol Cell Proteomics 9:2405-13
Yang, Da; Ylipaa, Antti; Yang, Jilong et al. (2010) An integrated study of aberrant gene copy number and gene expression in GIST and LMS. Technol Cancer Res Treat 9:171-8
Yang, Jilong; Du, Xiaoling; Chen, Kexin et al. (2009) Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett 275:1-8
Yang, Jilong; Du, Xiaoling; Lazar, Alexander J F et al. (2008) Genetic aberrations of gastrointestinal stromal tumors. Cancer 113:1532-43
Price, Nathan D; Trent, Jonathan; El-Naggar, Adel K et al. (2007) Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A 104:3414-9
Trent, Jonathan C; Ramdas, Latha; Dupart, Jheri et al. (2006) Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 107:1898-908
Steinert, Dejka M; Oyarzo, Mauricio; Wang, Xuemei et al. (2006) Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 106:1617-23
Nykter, Matti; Hunt, Kelly K; Pollock, Raphael E et al. (2006) Unsupervised analysis uncovers changes in histopathologic diagnosis in supervised genomic studies. Technol Cancer Res Treat 5:177-82
Koh, J S; Trent, J; Chen, L et al. (2004) Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 19:565-74